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Aims. The glycosphingolipid β-galactosylceramide-3-O-sulfate (sulfatide) is present in the secretory granules of the insulin
producing β-cells and may act as a molecular chaperone of insulin. The ﬁnal step in sulfatide synthesis is performed by cerebroside
sulfotransferase (CST) (EC 2.8.2.11). The aim of this study was to investigate whether two single nucleotide polymorphisms
(SNP), rs2267161 located in an exon or rs42929 located in an intron, in the gene encoding CST are linked to type 2 diabetes
(T2D). Methods. As a population survey, 265 male and female patients suﬀering from T2D and 291 gender matched controls were
examined. Results. A higher proportion of T2D patients were heterozygous at SNP rs2267161 with both T (methionine) and C
(valine) alleles present (49.8% versus 41.3%, P = .04). The calculated odd risk for T2D was 1.47 (1.01–2.15, P = .047). Among
femalecontrols,thehomozygousCCindividualsdisplayedlowerinsulinresistancemeasuredbyHOMA-IR(P = .05)thantheC/T
or TT persons; this was particularly prevalent in individuals who exercise (P = .03). Conclusion. Heterozygosity at SNP rs2267161
in the gene encoding the CST enzyme confers increased risk of T2D. Females with the CC allele showed lower insulin resistance.
Copyright © 2009 A. Roeske-Nielsen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Several single nucleotide polymorphisms (SNPs) have been
found linked to type 2 diabetes (T2D). These include calpain
10 [1], PPARγ [2], adiponectin [3, 4], and the Kir6.2 subunit
of the ATP-sensitive potassium channel [5]. In Icelandic
subjects, the transcription factor 7-like 2 (TCF7L2) was
found to be strongly associated to T2D [6].
The glycolipid β-galactosylceramide-3-O-sulfate (sul-
fatide) modulates cytokine expression [7–9], including TNF-
α and Interleukin 6 (IL-6) which are known to cause
insulin resistance [10]. Sulfatide may also act as a molecular
chaperone of insulin, being present in the secretory granules
and are secreted together with insulin [11, 12]. Low sulfatide
concentration in serum disposes to development of T2D
with a relative risk of 2.5, and low serum sulfatide levels are
correlated to high insulin resistance [13]. The cerebroside
sulfotransferase (CST) (EC 2.8.2.11) catalyzes the ﬁnal and
rate-limiting reaction in sulfatide synthesis: the addition of a
sulphate group to galactocylceramide, [14].
The gene encoding CST is located on chromosome
22 (22q12.2). The gene encompasses roughly 22kb and is
comprised of 8 exons, 6 noncoding, and 2 coding exons. The
CST cDNA, composed of 1791bp, encodes a 423-amino acid
protein with a predicted type II transmembrane topology
and 2 potential N-linked glycosylation sites. At present there
are13knownSNPsintheCSTgenebutonlyoneislocatedin
a coding exon (exon 7). This variation (rs2267161) causes an
amino acid shift at codon 29 alternating between methionine
and valine.2 Experimental Diabetes Research
Table 1: Nucleotide frequencies at SNPs rs2267161. Note diﬀerence in frequency of C/T genotype between controls and type 2 diabetic
patients. Asterisk indicates P <. 05.
rs2267161
C/C C/T T/T C T
Control
Male 0.485 0.382 0.132 0.676 0.324
Female 0.458 0.439 0.103 0.677 0.323
Male + Female 0.471 0.412∗ 0.117 0.677 0.323
DM
Male 0.432 0.482 0.086 0.673 0.327
Female 0.373 0.516 0.111 0.631 0.369
Male + Female 0.404 0.498∗ 0.098 0.653 0.347
Table 2: Associations between variations in the CST gene at SNPs rs2267161 and T2D. Associations were estimated using logistic regression
and expressed as odds ratios (ORs) with 95% conﬁdence intervals (CIs).
Category (covariates) Genotype C/C Genotype C/T Genotype T/T
ORs CIs p (C/T versus C/C) ORs CIs p (T/T versus C/C)
Men and women (age) 1 1.47 1.01–2.15 0.047 0.88 0.48–1.62 0.68
Men and women (age,
BMI)
1 1.50 1.01–2.24 0.045 0.85 0.45–1.60 0.61
Men and women (age,
exercise level)
1 1.59 1.07–2.35 0.02 0.90 0.48–1.69 0.74
Men and women (age,
Sulfatid)
1 1.44 0.98–2.12 0.07 0.85 0.46–1.58 0.61
Men and women (age,
HOMA-IR)
1 1.32 0.80–2.17 0.28 0.69 0.32–1.49 0.34
In this study we examined the prevalence of the two
SNPs rs2267161 and rs42929 in a group of 265 T2D
patients and 291 healthy controls. The individuals were
all examined intensively, with several clinical parameters
investigated, including BMI, insulin resistance (HOMA-IR),
serum sulfatide concentration, and exercise level.
2.MethodsandSubjects
2.1. Subjects. In Skara, Sweden, a large majority of patients
with hypertension and/or T2D have attended medical care
programs at the local public health center during the last 30
years. During 1992-1993, 400 patients diagnosed with dia-
betes were given extensively examinations at the health care
centre during an extended annual visit, thus participating
in the baseline survey of the Skaraborg Hypertension and
DiabetesProject,describedindetailelsewhere[15].Fromthe
population census register of Skara, 1400 subjects aged ≥40
years were randomly selected, stratiﬁed by age and gender
to participate in a population survey [16]. From each 10-
year category between 40 and 79 years of age, 150 men
and women, and in the age group 80 years, 100 men and
100 women were identiﬁed. These subjects were invited to
the clinic for a clinical examination according to the same
protocol as in the 1993-1994 patient survey. 1109 subjects
responded and completed the investigation. The Skaraborg
Hypertension and Diabetes Project have been approved by
the Committee on Research Ethics at the Medical Faculty of
G¨ oteborg University, andallparticipants gavetheirinformed
consent. Patients below 75 years of age with T2D were
eligible for the present study, and 128 women and 145 men
were selected as participants. From the population survey
300 control individuals conforming to the following were
selected: <75 years, no evidence of T2D and fasting blood
glucoselevel<5.6mmol/L, 142 women and 158 men in total.
Due to lack of biochemical analysis 4 men (1 patient and 3
controls) were excluded from the study at baseline, and a
further14wereexcludedduetofailureofgenotyping;intotal
136 male and 155 female controls partook, along with 139
male and 126 female T2D patients. There was a signiﬁcant
age diﬀerence between cases and controls, but within each
group the ages of men and women were similar.
2.2. Biomedical Data. Body mass index (BMI), blood serum
sulfatide concentrations, serum insulin concentration, and
fasting blood glucose levels were obtained as described in
[13].
2.3. Homeostasis Model Assessment Test (HOMA). Blood
samples were drawn in the morning, after 10 hours of
overnight fast. Fasting blood glucose was analyzed locally
by a modiﬁed glucose dehydrogenase method (Hemocue
AB, ¨ Angelholm, Sweden). Using the Homeostasis Model
Assessment (HOMA) [17, 18] insulin resistance and β-cell
function were assessed from the fasting glucose and insulin
concentrations. Patients with fasting blood glucose levels of
less than 3.5mmol/L and patients in treatment with insulin
(65 patients) were excluded from analysis of HOMA values.Experimental Diabetes Research 3
Table 3: HOMA-IR of controls and type 2 diabetic patients by sex, genotype, and level of exercise. ∗indicate P = .05, #indicate P = .03.
Gender Female Male
Genotype C/C Non-C/C C/C Non-C/C
Mean SD n Mean SD n C/C SD n Non-C/C SD n
Controls
All 0.75∗ 0.20 71 0.97 0.19 84 1.00 0.19 66 1.05 0.25 70
Exercise 0.52∗ 0.14 12 1.01 0.29 21 0.87 0.24 21 0.97 0.27 32
No-exercise 0.80 0.24 59 0.96 0.21 63 1.05 0.21 45 1.11 0.33 38
T2D
All 3.14 0.63 47 3.06 0.63 79 2.49 0.57 60 2.61 0.61 79
Exercise 2.88 0.68 8 2.21 0.74 4 3.03 0.90 14 2.04 0.63 14
No-exercise 3.18 0.66 39 3.08 0.65 75 2.37 0.59 46 2.74 0.72 63
Table 4: Biomedical data from patients and controls displayed according to genotype at SNPs rs2267161. The serum sulfatide and insulin
levels are in log units.
Genotype C/C Genotype C/T Genotype T/T
Controls Type 2 Controls Type 2 Controls Type 2
Male
n 66 — 60 — 52 — 67 — 18 — 12 —
mean SD mean SD mean SD mean SD mean SD mean SD
Age 58.5 10.4 63.9 7.9 57.7 9.6 65.8 6.8 56.2 10.2 66.9 6.1
BMI 26.3 2.8 28.3 4.1 26.6 3.1 28 4.3 26.1 2.2 28 5.7
Sulfatid 2.2 0.7 1.9 0.8 2.2 0.8 1.9 0.8 2.0 0.8 2.0 0.8
Serum insulin 0.7 0.3 0.9 0.4 0.7 0.4 1.0 0.6 0.6 0.4 1.0 0.2
Fasting blood glucose (mmol/L) 4.6 0.5 8.4 2.3 4.7 0.5 8.4 2.6 4.7 0.4 8.9 2.2
Female
n 71 — 47 — 68 — 65 — 16 — 14 —
mean SD mean SD mean SD mean SD mean SD mean SD
Age 58.9 9.7 65.3 8.1 57.7 10 64.1 8.7 61.1 10.9 68.3 5.4
BMI 27 5.6 29.2 5.4 26.5 4.5 29.9 4.7 26.3 4.7 31 4.7
Sulfatid 2.3 0.7 2.2 0.8 2.3 0.7 1.9 0.8 2.1 0.7 2 0.8
Serum insulin 0.6 0.5 1.0 0.3 0.7 0.3 1.1 0.4 0.8 0.4 0.9 0.3
Fasting blood glucose (mmol/L) 4.7 0.4 7.9 2.0 4.7 0.5 8.1 2.7 4.8 0.5 9.9 4.0
2.4. Exercise Level. A questionnaire on tobacco use, alcohol
consumption, and leisure time physical activity (LTPA) was
given to the participants when they came to the study visit.
They completed it on site and returned it to the study nurse.
LTPA was characterized based on four answer alternatives
to the question “How much physical activity do you engage
in during your leisure time?” The question referred to the
past year and the answer alternatives were as follows. (1)
Sedentary leisure time: reading, TV, stamp collecting, or
other sedentary activity. (2) Light LTPA: walking, cycling, or
other physical activity under at least four hours per week. (3)
ModerateLTPA:running,swimming,tennis,aerobic,heavier
gardening, or similar physical activity during at least 2 hours
a week. (4) Heavy training or competitive sport: heavy
training or competitions in running, skiing, swimming,
football, and so forth, which is performed regularly and
several times a week.
2.5. Polymorphism Screening. In total, 265 T2D samples
and 291 control samples were tested for the two SNPs
(rs2267161 and rs42929). Genotyping was performed using
multiplex PCR followed by matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF) using SEQUENOM’s MassEXTEND assay (Sequenom,
San Diego, Calif, USA). Brieﬂy, ampliﬁcation of genomic
DNA, forward and reverse primers speciﬁc for the sequence
surrounding the two SNPs were constructed, each primer
incorporated an hME-10 tag. The hME-10 primers were
used in the ﬁrst multiplex PCR. The ampliﬁed, DNA was
then treated with shrimp alkaline phosphatase to despho-
sphorylate any unincorporated dNTPs and subjected to a
secondmultiplexPCR.InthesecondmultiplexPCR,primers
speciﬁc for the DNA sequences forward or reverse up to
the SNPs were used along with terminating dNTPs, speciﬁc
for the polymorphic nucleotides, creating allele-speciﬁc
extension products. The molecular weights of the extension
products were subsequently analyzed using MALDI-TOF
mass spectrometry.
2.6. Statistics. Statistical analysis was performed using SPSS
12.0.1 for Windows. Standard methods were used for
descriptive statistics. All analyses were adjusted for diﬀerence
in age and speciﬁed also for other covariates. Associations
between categorical variables were analyzed by logistic
regression and expressed as odds ratios (ORs) with 95% con-
ﬁdence intervals (CIs). Diﬀerences in continuous variables
were analysed with general linear models (GLMs). All tests4 Experimental Diabetes Research
Table 5: The nucleotide frequencies at SNPs rs42929.
rs42929
C/C C/T T/T C T
Control
Male 0.902 0.090 0.008 0.947 0.053
Female 0.928 0.072 — 0.964 0.036
Male + Female 0.916 0.080 0.003 0.956 0.044
DM
Male 0.911 0.089 — 0.956 0.044
Female 0.894 0.098 0.008 0.943 0.057
Male + Female 0.903 0.093 0.004 0.949 0.050
were 2-sided, and statistical signiﬁcance was assumed when
P<. 05.
3. Results
Association between two SNPs in the cerebroside sulfo-
trasferase gene and T2D was examined. Regarding the SNPs
rs2267161, theheterozygoticalleleC/Twasfoundtobemore
frequent among the T2D patients than among the controls
(49.8% versus 41.3%, P = .04) (Table 1). The odd ratio
for having T2D increased from 1 (C/C) to 1.59 (conﬁdence
interval: 1.07–2.35) with the C/T genotype (P = .02), after
correcting for age, sex, and physical activity (Table 2).
All participants in the study completed a homeostasis
model assessment test (HOMA) for insulin resistance (-IR)
and β-cell function (-BC). In control females, subjects with
the C/C genotype displayed higher insulin sensitivity (P =
.02) and lower β-cell function (P = .05) than the C/T
or T/T genotypes (Table 3). Further analysis of the lower
insulin resistance amongst the female controls revealed that
the diﬀerence lays entirely amongst women who exercised,
(P = .03) (Table 3).
Sulfatide levels were signiﬁcantly lower in the patient
group compared to the control group (1.96 versus 2.22), but
thisdiﬀerencewasnotrelatedtoanyofthegenotypes,andno
signiﬁcant diﬀerence between the genotypes were observed
(see Table 4).
Analysis of rs42929 allele frequency data revealed no
signiﬁcant diﬀerence between diabetic patients and controls
(Table 5).
4. Discussion
Analysis of the allele frequency of the exon located SNPs
rs2267161 revealed a higher proportion of T2D patients
having the C/T allele than controls. Female controls with
the C/C genotype displayed better insulin sensitivity and
showed corresponding lower insulin secretion; exercise may
beespeciallybeneﬁcialfortheseindividualsasfemalecarriers
of the C/C genotype who exercised had lower insulin
resistance than carriers of the other genotypes. Interestingly,
the C/C allele tended to have a reduced frequency among the
female diabetic patients. T2D is correlated to obesity, with
women considerably more susceptible to increased risk with
increasing BMI [19] and women with T2D experience a 3-
fold higher risk of acute myocardial infarct than men with
T2D [20].
The SNPs rs2267161 causes an amino acid variance
betweenmethionineandvaline.Thepredominantgenotypes
are C/C and C/T coding for valine and valine and methion-
ine.ThehomozygoticTform(T/T)hasthelowestfrequency;
that is, T is the minor allele at re2267161. Both methionine
and valine are overall uncharged and have similar level
of hydrophobicity. Valine has a neutral ethyl-side group,
whereas methionine has a sulphanyl group. This diﬀerence
might lead to conformational changes in the CST enzyme
depending on which amino acid is used at SNPs rs2267161.
The precise functional consequence, at enzyme level, of
heterozygoticity at SNPs rs2267161 is not known, but the
observed diﬀerence between controls and the patient group
indicates that increased heterozygoticity confers an increased
risk of T2D in the population tested.
Other studies have reported a possible linkage between
chromosome 22 and T2D in genomewide linkage analy-
sis using microsatellite markers encompassing the region
22q12.2 where the CST gene is located. A UK-based study
found a linkage between a loci located at position 22q11
and early onset (<45 years) T2D; the resolution in this
study was an average of 9 centimorgans indicating that
region 22q12 could be included [21]. A genomic scan of
516 microsatellite markers in 363 Pima Indians revealed
a linkage between region 22q12-13 and fasting plasma
glucose concentration [22]. In a study including 638 T2D
aﬀected African-American sib-pairs, a genomewide multi-
point single-locus linkage analysis, the second highest LOD
scoreof1.33wasseenonchromosome22at32centimorgans
(microsatellite marker D22S685)—region 22q12 [23]. A
genomewide linkage search in Canadian Oji-Cree Indians
using 190 microsatellite markers (resolution approximately
20 centimorgans), marker D22S683 (encompassing region
22q12) showed signiﬁcant linkage to T2D [24]. Taken
together these reports substantiate our ﬁnding that region
22q12 is linked to T2D prevalence.
5. Conclusion
Sulfatide aﬀects both the immune system (including
low grade inﬂammation as seen in T2D) and β-cell
(pato)physiology [25], and the blood concentration ofExperimental Diabetes Research 5
sulfatide is reduced in T2D patients [13]. We here report a
connection between a speciﬁc genotype and changed insulin
resistance in females, linked to exercise level, and a linkage
between susceptibility to T2D and a heterozygosity in the
coding region of the CST gene, the ﬁnal step in sulfatide
synthesis.
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